Aerovate Therapeutics Inc expected to post a loss of 71 cents a share - Earnings Preview

Jade Biosciences

25/03/2024 11:07

* Aerovate Therapeutics Inc  AVTE.OQ   AVTE.O  is expected
to show
no change in quarterly revenue when it reports  results on March
27 (estimated) for the period ending December 31 2023
    * 
    * ​LSEG's mean analyst estimate for Aerovate Therapeutics
Inc is
for a loss of 71 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 7 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Aerovate
Therapeutics Inc is $35.50​, above​ its last closing price
of $25.78. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.70       -0.69      -0.71     Missed  -2.7
 Jun. 30 2023  -0.70       -0.70      -0.76     Missed  -9.2
 Mar. 31 2023  -0.61       -0.60      -0.67     Missed  -11.7​
 Dec. 31 2022  -0.71       -0.62      -0.61     Beat    1.3
 ​​Sep.        -0.50       -0.50      -0.56     Missed  -12.4
 30 2022                                                
 Jun. 30 2022  -0.46       -0.45      -0.49     Missed  -7.8​
 Mar. 31 2022  -0.34       -0.28      -0.45     Missed  -62.2
 Dec. 31 2021  -0.26       -0.31      -0.35     Missed  -13.8
 This summary was machine generated March 25 at 11:07 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)